BioSpace News Archive

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 12:30 p.m. ET.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J. Slack, PhD, to its advisory board.

For the third year, CSL Plasma will provide influenza vaccination vouchers to U.S. plasma donors following the completion of two plasma donations made within a calendar month.

Longhorn Vaccines and Diagnostics LLC, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, announced that Zoe Silver has joined the company as Senior Vice President of Genomics & Diagnostics.

NLS Pharmaceutics Ltd. announces that Dr. George Apostol has been appointed to the position of Chief Medical Officer and Global Head of Research and Development.

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in notalgia paresthetica (NP).

New detailed results from Eli Lilly and Company’s (NYSE: LLY) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational lebrikizumab provided robust and durable improvements in skin clearance and itch for patients who achieved a clinical response* at Week 16 through one year of treatment.

Biofidelity, a revolutionary genomic technology company dedicated to unleashing the potential of genomics to transform human health and the world we live in, announced the issuance of several new patents in the US, Europe, and China.

LEO Pharma A/S, a global leader in medical dermatology, today announced new safety data for AdbryTM (tralokinumab-ldrm) for adult patients with moderate-to-severe atopic dermatitis (AD).

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, announced that senior management will present a company overview at two upcoming investor conferences.